CJC-1295 with DAC – Research-Grade Long-Acting GHRH Analog

CJC-1295 with DAC is a synthetically modified growth hormone–releasing hormone (GHRH) analog incorporating a Drug Affinity Complex (DAC) conjugation. The DAC modification enables covalent interaction with circulating albumin in experimental models, resulting in an extended peptide persistence profile compared to non-conjugated GHRH fragments.

In laboratory research environments, CJC-1295 with DAC is utilized as a reference material for studying receptor–ligand interaction dynamics, peptide half-life modification strategies, and structure–function relationships associated with long-acting peptide analog systems.

Unlike short native peptide fragments, CJC-1295 with DAC represents a chemically engineered conjugated peptide construct designed to support controlled in vitro and mechanistic research. This material is intended strictly for laboratory research use only and is not designed for human or veterinary application.